Story
Nvidia CEO Rebuts Vera Rubin Delay Reports, Says AI Platform Is in Production

Summary
Nvidia CEO Jensen Huang has pushed back against reports of a manufacturing delay for the company's next-generation Vera Rubin AI platform, stating that it is already in production. The comments, made at an event in Tokyo, also addressed the status of H200 chip shipments to China.
Nvidia (NASDAQ:NVDA) CEO Jensen Huang on Wednesday forcefully denied reports that the company’s next-generation Vera Rubin AI accelerator system is facing manufacturing delays, stating the platform is already being produced. The remarks, made to reporters in Tokyo, directly counter a recent claim from a prominent research firm that suggested a setback in the company's product roadmap.
Production Status and Market Stakes
At a developer event, Huang declared, "Vera Rubin is already in production. Giant amounts of production incoming," according to a report from Bloomberg. This statement refutes a report from research firm SemiAnalysis, which had claimed the Vera Rubin AI server rack system was delayed due to challenges in manufacturing a specialized circuit board.
Any significant delay to Nvidia's product cycle could create an opening for competitors like AMD, which is advancing its MI350 and MI400 accelerators. For investors, Huang's on-the-record denial is highly consequential, as Nvidia's elevated market valuation is closely tied to its ability to execute its aggressive product release schedule. The specific technical issue cited by SemiAnalysis—advanced component packaging—has historically been a bottleneck in semiconductor manufacturing.
China Shipments and Strategic Context
Huang also provided an update on shipments of the H200 AI chip to China, which have been under intense scrutiny following an easing of U.S. export restrictions. Despite Washington clearing the chip for export in December, Huang indicated the ramp-up is in its early stages. "We haven't really started much shipment yet," he told reporters, as noted by Bloomberg.
AdThe comments were delivered in Tokyo, a strategically important market for Nvidia as Japan pursues major investments in AI and robotics. According to Bloomberg, Japan's government has announced a $2.3 trillion spending plan to boost private sector AI investment, highlighting the region's focus on automation and technology where Nvidia's platforms are key.
Investor Implications
Investors are now left with two key signals to monitor. On Vera Rubin, Huang’s definitive statement sets up a credibility test between the CEO and SemiAnalysis, a firm known for its supply chain analysis. However, without a specific delivery timeline or public confirmation from major customers, the debate over the production ramp may continue until hyperscalers confirm deployments.
Regarding China, the trajectory of H200 shipments will be a closely watched potential revenue catalyst. China was a significant source of data center revenue for Nvidia before strict export controls were imposed, and a successful ramp-up could provide a meaningful boost to the company's upcoming financial results.
Read next
More on Stocks
Apple's Tim Cook Views Australia's Social Media Curbs as 'World-Leading,' PM Albanese Says
Apple Executive Chair Tim Cook praised Australia's pioneering online safety measures as "world-leading," according to Prime Minister Anthony Albanese following a meeting at the tech giant's California headquarters.

Venezuela's Interim Government Signs Energy MOU with TotalEnergies
Venezuela's interim government signed a memorandum of understanding with French energy major TotalEnergies, the latest in a series of deals aimed at attracting foreign investment back into the nation's vast oil sector.

Huawei Unveils Advanced Power and Cooling Solutions for AI Data Centers
Huawei has launched a new suite of energy infrastructure and thermal management products for AI data centers, signaling a strategic shift towards integrated power storage and intelligent liquid cooling systems to meet the demands of high-density computing.

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.